VEGF-A121 ASSAY

摘要

The invention provides a method for enriching the level of VEGF-A121 isoform in a sample by selectively removing the VEGF-A165 isoform from the sample using a neuropilin-1 pull-down procedure, then determining the total amount of VEGF-A remaining afterward. The invention provides methods of treating a patient suffering from a disease which may benefit from the administration of a VEGF antagonist by determining the level or ratio of VEGF-A121 in the patient's circulation. Methods of diagnosis, prognosis, monitoring, and patient stratification are also provided.

主权项

1. A method of selecting a patient capable of responding to VEGF antagonist therapy comprising the steps of (a) obtaining a blood sample from a patient who suffers from cancer; (b) enriching the amount of VEGF-A121 in a total amount of VEGF-A in the sample by the steps of: (i) contacting the sample comprising VEGF-A165 and VEGF-A121 with (1) a neuropilin 1 (“NRP1”) protein, or (2) a fraction of the NRP1 protein comprising the B1 B2 domain, wherein the VEGF-A165 binds to the NRP1 protein or fraction thereof to form a NRP1 —VEGF-A165 complex; and (ii) separating the sample from the NRP1 —VEGF-A165 complex to form a VEGF-A165-depleted sample; (c) determining the total amount of VEGF-A enriched for VEGF-A1 21 in the sample, and (d) selecting a patient whose sample contains a total amount of VEGF-A enriched for VEGF-A1 21 at or above a threshold level, wherein said patient is more likely to respond favorably to VEGF antagonist therapy than a patient having an amount of total VEGF-A enriched for VEGF-A1 21 below the threshold level.